Maker of micro-invasive glaucoma surgery (MIGS) devices and emerging corneal health/myopia therapies.
Maker of micro-invasive glaucoma surgery (MIGS) devices and emerging corneal health/myopia therapies.
Sells small implants that surgeons use during eye surgery, per procedure, so revenue follows glaucoma-surgery volumes, mainly in the US. Moving from iStent stents toward iDose TR, an implant that releases the drug for months to years, shifts the company from devices toward a pharma-like product. Corneal-health and myopia treatments are further out.
Moat: narrow (IP / patents, switching costs). Pioneer and share leader in the MIGS device category with strong surgeon relationships.
Headquarters: Aliso Viejo, California, USA · Founded: 1998 · Employees: 1,094
Size Glaukos (GKOS) is a United States Health Care company (Medical Specialties) with a market value of $13.8B, the 631st largest of 3,085 United States companies the cockpit tracks. Shares closed at $233.08 on 18 Nov 2026.
Performance Over six months the shares gained 62.1%, against +26.2% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 46.9% over the last twelve months (peer median +4.6%); the operating margin is -8.9% (peer median 16.4%).
Valuation It trades at 161.5× forward earnings against a peer median of 20.0× (most expensive of 20).
Capital Return on invested capital runs 18.6 points below its cost of capital (8.5% WACC).
Short interest Short interest is 7.6% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $690M | $507M | $383M | $315M | $283M |
| Revenue growth | — | +32% | +22% | +11% | — |
| Gross profit | $560M | $393M | $287M | $237M | $211M |
| EBITDA | -$15.5M | -$44.4M | -$68.2M | -$85.7M | -$66.4M |
| Net income | -$170M | -$188M | -$146M | -$135M | -$99.2M |
| Free cash flow | $19.4M | -$39.1M | -$67.6M | -$78.0M | -$63.3M |
| Capital expenditure | $28.3M | $24.3M | $6.30M | $20.2M | $30.3M |
| Total debt | $102M | $107M | $106M | $385M | $383M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Glaukos GKOS | $13.8B | +62% | +47% | -9% | 161.5× | n/a |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Sight Sciences SGHT | $599M | +122% | +16% | -30% | n/a | n/a |
| Santen Pharmaceutical 4536.T | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Ocular Therapeutix OCUL | $1.31B | -26% | -10% | -681% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GKOS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +34.4% | +4.4% | highest of 21 |
| 6-month return | +62.1% | +26.2% | 2nd highest of 21 |
| Distance from 52-week high | -8.7% | -13.5% | 6th highest of 21 |
| Revenue growth (TTM) | +46.9% | +4.6% | highest of 21 |
| Operating margin | -8.9% | 16.4% | 2nd lowest of 21 |
| Forward P/E | 161.5× | 20.0× | most expensive of 20 |
| ROIC minus cost of capital | -18.6 pp | +0.9 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |